Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of mezagitamab in adults with chronic primary immune thrombocytopenia
NL-OMON60376Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mezagitamab in chronic primary immune thrombocytopenia (ITP), sponsored by Takeda. Primary endpoints: Occurrence of treatment-emergent adverse events and serious treatment-emergent adverse events and Occurrence of treatment-emergent adverse events leading to permanent withdrawal of mezagitamab. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mezagitamab
03
Conditions
chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON60376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60376.